Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PHARMACOLOGY AND ANTITUMOR EFFECTS OF INTRAPORTAL PIRARUBICIN ON EXPERIMENTAL LIVER METASTASES
Autore:
RAMIREZ LH; MUNCK JN; BOGNEL C; ZHAO Z; ARDOUIN P; POUPON MF; GOUYETTE A; ROUGIER P;
Indirizzi:
INST GUSTAVE ROUSSY,DEPT MED,RUE CAMILLE DESMOULINS F-94805 VILLEJUIFFRANCE INST GUSTAVE ROUSSY,DEPT MED,RUE CAMILLE DESMOULINS F-94805 VILLEJUIFFRANCE INST GUSTAVE ROUSSY,DEPT ANATOMOPATHOL F-94805 VILLEJUIF FRANCE INST GUSTAVE ROUSSY,SERV EXPERIMENTAT ANIM F-94805 VILLEJUIF FRANCE INST GUSTAVE ROUSSY,INSERM,U140,PHARMACOL CLIN LAB F-94805 VILLEJUIF FRANCE INST GUSTAVE ROUSSY,CNRS,URA 147 F-94805 VILLEJUIF FRANCE INST CURIE,CNRS,URA 620 F-75005 PARIS FRANCE
Titolo Testata:
British Journal of Cancer
fascicolo: 2, volume: 68, anno: 1993,
pagine: 277 - 281
SICI:
0007-0920(1993)68:2<277:PAAEOI>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
RANDOMIZED CONTROLLED TRIAL; PORTAL-VEIN; COLORECTAL-CANCER; ADJUVANT CHEMOTHERAPY; CURATIVE RESECTION; HEPATIC-ARTERY; INFUSION; ADENOCARCINOMA; CIRCULATION; CARCINOMA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
25
Recensione:
Indirizzi per estratti:
Citazione:
L.H. Ramirez et al., "PHARMACOLOGY AND ANTITUMOR EFFECTS OF INTRAPORTAL PIRARUBICIN ON EXPERIMENTAL LIVER METASTASES", British Journal of Cancer, 68(2), 1993, pp. 277-281

Abstract

Early liver metastases have a predominant portal blood supply. Intraportal (i.port.) vein administration of cytotoxics could theoretically achieve enhanced drug concentrations in tumour cells and be effective as adjuvant therapy after resection of colorectal carcinoma. Pirarubicin (which has a higher hepatic extraction than doxorubicin) was investigated on liver metastases of the VX2 rabbit tumour, which were of less than 2 mm in diameter 7 days after cells injection into the portal vein. To evaluate antitumour activity, 24 rabbits were randomised into three groups 7 days after implantation: (a) control, (b) i.v. pirarubicin, (c) i.port. pirarubicin at doses of 2 mg kg-1 in both groups. Portal infusions led to no hematological or hepatic toxicity. Pharmacokinetic parameters showed a significantly reduced systemic exposure afteri.port. administration. Fourteen days after treatment, livers and lungs were analysed. The mean number (+/- s.d.) of tumour foci was (a) 8.62 (+/- 5.4), (b) 4.62 (+/- 3.2), (c) 2.25 (+- 1.4) (P<0.05 a vs c). The mean tumour area was (a) 6.31 (+/- 6.1), (b) 1.31 (+/- 2.2), (c) 0.43 (+/- 0.4 cm2) (P<0.05 a vs c) and the percentage (95% C.I.) of rabbits with lung metastasis was: (a) 87.5% (47-99%), (b) 75% (35-97%), (c) 12.5% (3-52%) (P<0.02 b vs c). Intraportal pirarubicin seems to be well tolerated and more efficient than i.v. administration, particularly in preventing extrahepatic dissemination.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 04:34:26